AngioDynamics, Inc. (ANGO)
| Market Cap | 458.92M |
| Revenue (ttm) | 313.73M |
| Net Income (ttm) | -31.39M |
| Shares Out | 41.68M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 141,343 |
| Open | 11.07 |
| Previous Close | 11.09 |
| Day's Range | 10.99 - 11.15 |
| 52-Week Range | 8.36 - 13.99 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+63.49%) |
| Earnings Date | Apr 2, 2026 |
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device tha... [Read more]
Financial Performance
In fiscal year 2025, AngioDynamics's revenue was $292.50 million, a decrease of -3.76% compared to the previous year's $303.91 million. Losses were -$33.99 million, -81.56% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 63.49% from the latest price.
News
AngioDynamics Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has transformed its portfolio, focusing on high-growth MedTech segments and innovative devices for cardiovascular and oncology markets. Strong financials, ongoing product innovation, and market expansion position it for sustained growth and margin improvement.
AngioDynamics Earnings Call Transcript: Q3 2026
Third quarter revenue grew 8.9% year-over-year, led by MedTech segment strength and robust growth in Auryon, AlphaVac, and NanoKnife. Full-year guidance for net sales and adjusted EBITDA was raised for the third consecutive quarter, with strong cash and no debt.
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Transcript: Leerink Global Healthcare Conference 2026
The business has transformed into a tech-focused med tech company, driving strong growth in cardiovascular and oncology platforms. Med Tech products are outperforming expectations, with Auryon and AlphaVac leading expansion, while NanoKnife is gaining traction in prostate cancer and BPH. Robust R&D and a growing sales force support continued momentum.
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: 44th Annual J.P. Morgan Healthcare Conference
A science-driven transformation has positioned the company for strong growth, with MedTech now driving over 45% of revenue and expanding rapidly. Key products like Auryon, AlphaVac, and NanoKnife are gaining market share, while financial performance is improving with positive EBITDA and cash flow. Leadership transition is underway, but the outlook remains robust.
AngioDynamics Earnings Call Transcript: Q2 2026
Revenue grew 8.8% year-over-year, led by Med Tech and Auryon platform strength, with gross margin up 170 bps and adjusted EBITDA nearly doubling. Full-year guidance for revenue and EBITDA was raised, and key regulatory milestones were achieved in mechanical thrombectomy. Leadership transition was announced.
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
AngioDynamics, Inc. (NASDAQ: ANGO) will release earnings results for its second quarter before the opening bell on Tuesday, Jan. 6, 2026.
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: UBS Global Healthcare Conference 2025
A focused MedTech strategy has driven strong growth, with the MedTech segment now nearing half of total revenue and expected to become the largest segment. Key platforms in oncology, PAD, and thrombectomy are expanding through innovation and clinical data, supporting double-digit growth and margin expansion.
AngioDynamics to Participate in the UBS Global Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.
AngioDynamics Earnings Call Transcript: Q1 2026
Revenue grew 12.2% year-over-year to $75.7 million, led by 26% med-tech growth and strong gains in mechanical thrombectomy and NanoKnife. Gross margin improved to 55.3%, and guidance for fiscal 2026 was raised, reflecting confidence in continued segment momentum.
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings
AngioDynamics, Inc. (NASDAQ:ANGO) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 2.
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Transcript: Canaccord Genuity’s 45th Annual Growth Conference
A company in transformation is driving double-digit growth in Med Tech by focusing on innovative cardiovascular and oncology solutions, expanding its addressable market, and achieving positive EBITDA and cash flow. Key products like AlphaVac, Auryon, and NanoKnife are set for continued growth in FY 2026.